Methylation of RBM39 by PRMT6 enhances resistance to Indisulam in non-small cell lung cancer by promoting alternative splicing of proto-oncogenes
PLOS Biology · 2025
DOI: 10.1371/journal.pbio.3002846 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS Biology, 2025. Verfasst von Tongjia Zhang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Beijing Key Laboratory of Protein Posttranslational Modifications…. Hauptthemen laut MEDLINE: RNA-Binding Proteins, Alternative Splicing, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Beijing Natural Science Foundation, Beijing Natural Science Foundation Grant.
Abstract (Originalsprache)
Indisulam, a sulfonamide-based compound, is employed as a second-line therapy for NSCLC due to its anti-tumor activity. However, its clinical efficacy is hindered by acquired resistance, the molecular basis of which remains poorly understood. Here, we demonstrate that hypermethylation of RNA-binding protein 39 (RBM39), a specific target of Indisulam, is closely associated with Indisulam resistance. PRMT6 methylates RBM39 at R92. This methylation inhibits Indisulam-induced ubiquitination and proteasomal degradation of RBM39, increases RBM39 protein levels, promotes alternative splicing and expression of proto-oncogenes, and ultimately leads to malignant proliferation and metastasis of NSCLC cells and tumor growth in xenograft mouse models. Inhibiting PRMT6 with MS023 or mutating the RBM39 methylation site enhances Indisulam sensitivity in NSCLC and significantly improves its anti-tumor efficacy. Our findings identify methylated RBM39 as a key biomarker of Indisulam resistance and suggest a potential therapeutic strategy for NSCLC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Beijing Key Laboratory of Protein Posttranslational Modifications and Cell Function, Peking University Health Science Center, Beijing,…
ORCID-Profile: Xiaowei Zhang
Förderung
- National Natural Science Foundation of China
- Beijing Natural Science Foundation
- Beijing Natural Science Foundation Grant
Zitieren
APA
Zhang, T., Wang, S., Zhou, Y., Jiao, Z., Lu, K., Liu, X., Li, H., Jiang, W., & Zhang, X. (2025). Methylation of RBM39 by PRMT6 enhances resistance to Indisulam in non-small cell lung cancer by promoting alternative splicing of proto-oncogenes. PLOS Biology. https://doi.org/10.1371/journal.pbio.3002846
Vancouver
Zhang T, Wang S, Zhou Y, Jiao Z, Lu K, Liu X, et al. Methylation of RBM39 by PRMT6 enhances resistance to Indisulam in non-small cell lung cancer by promoting alternative splicing of proto-oncogenes. PLOS Biology. 2025. doi:10.1371/journal.pbio.3002846
BibTeX
@article{Zhang2025,
author = {Zhang, Tongjia and Wang, Shujie and Zhou, Yue and Jiao, Zitao and Lu, Kejia and Liu, Xinyi and Li, Hui and Jiang, Wei and Zhang, Xiaowei},
title = {Methylation of RBM39 by PRMT6 enhances resistance to Indisulam in non-small cell lung cancer by promoting alternative splicing of proto-oncogenes},
journal = {PLOS Biology},
year = {2025},
doi = {10.1371/journal.pbio.3002846}
}
EUVIMED